Gruppo Italiano Malattie Ematologiche Dell'adulto
Clinical trials sponsored by Gruppo Italiano Malattie Ematologiche Dell'adulto, explained in plain language.
-
Real-World check: Asciminib's performance in Tough-to-Treat CML
Disease control Not yet recruitingThis study will follow about 98 adults with chronic myeloid leukemia who are taking asciminib after other treatments have stopped working. Researchers want to see how many patients achieve a major molecular response (a key sign of disease control) after two years. The goal is to …
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World data sought on Ponatinib's impact against rare leukemia
Disease control Not yet recruitingThis study reviews medical records of 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received ponatinib as their first treatment in regular care. Researchers want to see how many patients achieve a complete molecular response (undetectable leukem…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New DNA test could spot leukemia resistance earlier
Diagnosis Not yet recruitingThis study will test whether a highly sensitive genetic test called digital PCR can detect drug-resistant mutations in people with chronic myeloid leukemia (CML) as well as the current standard method. Researchers will analyze blood samples from 150 adults with CML whose current …
Phase: NA • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Diagnosis
Last updated Jun 26, 2026 14:03 UTC
-
Italian study to track CAR-T success in leukemia patients
Knowledge-focused Not yet recruitingThis observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to unders…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study monitors infection risks in advanced myeloma drug
Knowledge-focused Not yet recruitingThis Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Momelotinib under the microscope: Real-World spleen shrinkage in myelofibrosis
Knowledge-focused Not yet recruitingThis study will observe 93 adults with myelofibrosis who are taking momelotinib as part of their normal care. Researchers will track how well the drug reduces spleen size after 6 months, providing real-world evidence of its effectiveness.
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC